Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Short term Debt (2020 - 2024)

Syndax Pharmaceuticals has reported Short term Debt over the past 5 years, most recently at $12.1 million for Q4 2024.

  • Quarterly results put Short term Debt at $12.1 million for Q4 2024, changed N/A from a year ago — trailing twelve months through Dec 2024 was $12.1 million (changed N/A YoY), and the annual figure for FY2024 was $12.1 million, changed.
  • Short term Debt for Q4 2024 was $12.1 million at Syndax Pharmaceuticals, up from $7.2 million in the prior quarter.
  • Over the last five years, Short term Debt for SNDX hit a ceiling of $12.1 million in Q4 2024 and a floor of $187000.0 in Q4 2021.
  • Median Short term Debt over the past 4 years was $5.8 million (2021), compared with a mean of $5.8 million.
  • Biggest five-year swings in Short term Debt: tumbled 91.82% in 2021 and later grew 2.59% in 2022.
  • Syndax Pharmaceuticals' Short term Debt stood at $2.3 million in 2020, then tumbled by 91.82% to $187000.0 in 2021, then skyrocketed by 3756.68% to $7.2 million in 2022, then surged by 68.0% to $12.1 million in 2024.
  • The last three reported values for Short term Debt were $12.1 million (Q4 2024), $7.2 million (Q2 2022), and $3.6 million (Q1 2022) per Business Quant data.